Distinct States of Nucleolar Stress Induced by Anticancer Drugs

Overview

Journal Elife

Specialty Biology

Date 2023 Dec 15

PMID 38099650

Authors

Tamara A Potapova

Jay R Unruh

Juliana Conkright-Fincham

Charles A S Banks

Laurence Florens

David Alan Schneider

Jennifer L Gerton

Affiliations

Soon will be listed here.

Abstract

Ribosome biogenesis is a vital and highly energy-consuming cellular function occurring primarily in the nucleolus. Cancer cells have an elevated demand for ribosomes to sustain continuous proliferation. This study evaluated the impact of existing anticancer drugs on the nucleolus by screening a library of anticancer compounds for drugs that induce nucleolar stress. For a readout, a novel parameter termed 'nucleolar normality score' was developed that measures the ratio of the fibrillar center and granular component proteins in the nucleolus and nucleoplasm. Multiple classes of drugs were found to induce nucleolar stress, including DNA intercalators, inhibitors of mTOR/PI3K, heat shock proteins, proteasome, and cyclin-dependent kinases (CDKs). Each class of drugs induced morphologically and molecularly distinct states of nucleolar stress accompanied by changes in nucleolar biophysical properties. In-depth characterization focused on the nucleolar stress induced by inhibition of transcriptional CDKs, particularly CDK9, the main CDK that regulates RNA Pol II. Multiple CDK substrates were identified in the nucleolus, including RNA Pol I- recruiting protein Treacle, which was phosphorylated by CDK9 in vitro. These results revealed a concerted regulation of RNA Pol I and Pol II by transcriptional CDKs. Our findings exposed many classes of chemotherapy compounds that are capable of inducing nucleolar stress, and we recommend considering this in anticancer drug development.

Citing Articles

Topological stress triggers persistent DNA lesions in ribosomal DNA with ensuing formation of PML-nucleolar compartment.

Urbancokova A, Hornofova T, Novak J, Salajkova S, Hubackova S, Uvizl A Elife. 2024; 12.

PMID: 39388244 PMC: 11466457. DOI: 10.7554/eLife.91304.

Mapping and engineering RNA-controlled architecture of the multiphase nucleolus.

Quinodoz S, Jiang L, Abu-Alfa A, Comi T, Zhao H, Yu Q bioRxiv. 2024; .

PMID: 39386460 PMC: 11463421. DOI: 10.1101/2024.09.28.615444.

The unique Pt(II)-induced nucleolar stress response and its deviation from DNA damage response pathways.

Pigg H, Alley K, Griffin C, Moon C, Kraske S, DeRose V J Biol Chem. 2024; 300(11):107858.

PMID: 39374783 PMC: 11612370. DOI: 10.1016/j.jbc.2024.107858.

The Nucleolus and Its Interactions with Viral Proteins Required for Successful Infection.

Ulloa-Aguilar J, Herrera Moro Huitron L, Benitez-Zeferino R, Cerna-Cortes J, Garcia-Cordero J, Leon-Reyes G Cells. 2024; 13(18.

PMID: 39329772 PMC: 11430610. DOI: 10.3390/cells13181591.

Regulators of rDNA array morphology in fission yeast.

Cockrell A, Lange J, Wood C, Mattingly M, McCroskey S, Bradford W PLoS Genet. 2024; 20(7):e1011331.

PMID: 38968290 PMC: 11253961. DOI: 10.1371/journal.pgen.1011331.

References

Ferreira R, Schneekloth Jr J, Panov K, Hannan K, Hannan R . Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age. Cells. 2020; 9(2). PMC: 7072222. DOI: 10.3390/cells9020266. View

Pelletier J, Thomas G, Volarevic S . Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2017; 18(1):51-63. DOI: 10.1038/nrc.2017.104. View

Bacon C, DOrso I . CDK9: a signaling hub for transcriptional control. Transcription. 2018; 10(2):57-75. PMC: 6602564. DOI: 10.1080/21541264.2018.1523668. View

Wei T, Najmi S, Liu H, Peltonen K, Kucerova A, Schneider D . Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint. Cell Rep. 2018; 23(2):404-414. PMC: 6016085. DOI: 10.1016/j.celrep.2018.03.066. View

Noack Watt K, Achilleos A, Neben C, Merrill A, Trainor P . The Roles of RNA Polymerase I and III Subunits Polr1c and Polr1d in Craniofacial Development and in Zebrafish Models of Treacher Collins Syndrome. PLoS Genet. 2016; 12(7):e1006187. PMC: 4957770. DOI: 10.1371/journal.pgen.1006187. View

Latonen L, Moore H, Bai B, Jaamaa S, Laiho M . Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene. 2010; 30(7):790-805. DOI: 10.1038/onc.2010.469. View

Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K . Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007; 448(7155):811-5. DOI: 10.1038/nature06046. View

Frottin F, Schueder F, Tiwary S, Gupta R, Korner R, Schlichthaerle T . The nucleolus functions as a phase-separated protein quality control compartment. Science. 2019; 365(6451):342-347. DOI: 10.1126/science.aaw9157. View

Fomproix N, Hernandez-Verdun D . When rDNA transcription is arrested during mitosis, UBF is still associated with non-condensed rDNA. J Cell Sci. 1997; 110 ( Pt 19):2429-40. DOI: 10.1242/jcs.110.19.2429. View

10.

Whittaker S, Mallinger A, Workman P, Clarke P . Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017; 173:83-105. PMC: 6141011. DOI: 10.1016/j.pharmthera.2017.02.008. View

11.

Roussel P, Andre C, Masson C, Geraud G, Hernandez-Verdun D . Localization of the RNA polymerase I transcription factor hUBF during the cell cycle. J Cell Sci. 1993; 104 ( Pt 2):327-37. DOI: 10.1242/jcs.104.2.327. View

12.

Jao C, Salic A . Exploring RNA transcription and turnover in vivo by using click chemistry. Proc Natl Acad Sci U S A. 2008; 105(41):15779-84. PMC: 2572917. DOI: 10.1073/pnas.0808480105. View

13.

Shapiro G, Koestner D, Matranga C, Rollins B . Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 1999; 5(10):2925-38. View

14.

Drygin D, Lin A, Bliesath J, Ho C, OBrien S, Proffitt C . Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2010; 71(4):1418-30. DOI: 10.1158/0008-5472.CAN-10-1728. View

15.

Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A . Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. Eur J Med Chem. 2018; 158:896-916. DOI: 10.1016/j.ejmech.2018.09.025. View

16.

Guo Y, Manteiga J, Henninger J, Sabari B, DallAgnese A, Hannett N . Pol II phosphorylation regulates a switch between transcriptional and splicing condensates. Nature. 2019; 572(7770):543-548. PMC: 6706314. DOI: 10.1038/s41586-019-1464-0. View

17.

Jorda R, Hendrychova D, Voller J, Reznickova E, Gucky T, Krystof V . How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?. J Med Chem. 2018; 61(20):9105-9120. DOI: 10.1021/acs.jmedchem.8b00049. View

18.

Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Lleres D . The cell proliferation antigen Ki-67 organises heterochromatin. Elife. 2016; 5:e13722. PMC: 4841783. DOI: 10.7554/eLife.13722. View

19.

Andrews W, Ray S, Panova T, Engel C, Panov K . DNA Intercalators Inhibit Eukaryotic Ribosomal RNA Synthesis by Impairing the Initiation of Transcription. Genes (Basel). 2021; 12(9). PMC: 8466728. DOI: 10.3390/genes12091412. View

20.

Burger K, Muhl B, Rohrmoser M, Coordes B, Heidemann M, Kellner M . Cyclin-dependent kinase 9 links RNA polymerase II transcription to processing of ribosomal RNA. J Biol Chem. 2013; 288(29):21173-21183. PMC: 3774383. DOI: 10.1074/jbc.M113.483719. View